


ISSUE DATE August 29, 2022	EFFECTIVE DATE August 29, 2022	NUMBER 08-22-19
SUBJECT Naloxone Distribution by Federally Qualified Health Centers and Rural Health Clinics		BY  Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) of updates to the Medical Assistance (MA) Program Fee Schedule relating to the distribution of take-home supplies of nasal or injectable naloxone to MA beneficiaries.

This MA Bulletin obsoletes [MA Bulletin 08-21-07](#), titled “Naloxone Distribution by Federally Qualified Health Centers and Rural Health Clinics,” issued October 21, 2021.

SCOPE:

This bulletin applies to MA enrolled FQHCs and RHCs that provide services to MA beneficiaries in the MA Program’s fee-for-service and managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND:

To support the provision of services in an opioid treatment program, MA enrolled FQHCs and RHCs are to bill for the provision of a take-home supply of nasal or injectable naloxone to MA beneficiaries. However, as these services are to be provided as part of a FQHC or RHC billable encounter and are included as part of the FQHC’s or RHC’s

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

Fee-for-service provider service center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>.

Prospective Payment System (PPS) rate under procedure code T1015, the Department of Human Services (Department) did not previously have a method in place to track the provision of an opioid treatment supply in the FQHC and RHC settings.

On October 21, 2021, the Department issued MA Bulletin 08-21-07, which informed FQHCs and RHCs of two Healthcare Common Procedure Coding System (HCPCS) procedure codes to identify the distribution of a take-home supply of nasal or injectable naloxone. These codes were added as part of the Department's 2021 HCPCS update to enable the Department to identify the provision of a take-home opioid treatment supply to MA beneficiaries.

DISCUSSION:

The Department issued MA Bulletin 99-22-05, titled "2022 Healthcare Common Procedure Coding System (HCPCS) Updates, Fee Adjustments and Other Procedure Code Changes" to announce changes to the MA Program Fee Schedule, effective with dates of service on and after August 29, 2022.

As a result, the Department updated the MA Program Fee Schedule to reflect the procedure codes for naloxone distribution in the FQHC or RHC setting. Procedure code G1028 is being added to the MA Program Fee Schedule for the submission of claims that include the provision of a take-home supply of naloxone for MA beneficiaries, and the description of procedure code G2215 is being updated. Procedure code G2216 remains in effect with no changes.

PROCEDURE:

FQHCs and RHCs are to bill procedure code T1015 to receive payment based on their provider-specific PPS payment rate, when providing an encounter that includes providing beneficiaries with a take-home supply of naloxone. In addition, they are to include the appropriate zero-pay HCPCS code on a separate claim line so the Department can track the distribution.

<u>Code</u>	<u>Code Description</u>
G1028	Take-home supply of nasal naloxone; 2-pack of 8 mg per 0.1 ml nasal spray (provision of the services by a Medicare-enrolled Opioid Treatment Program); list separately in addition to code for primary procedure
G2215	Take home supply of nasal naloxone; 2-pack of 4 mg per 0.1 ml nasal spray (provision of the services by a Medicare-enrolled Opioid Treatment Program); list separately in addition to code for primary procedure

G2216	Take home supply of injectable naloxone (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
-------	--

Providers may access the online version of the MA Program Fee Schedule at: <https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

FQHCs and RHCs are to refer to the billing instructions in this MA Bulletin and instructions in the [MA Program's Provider Handbook and Billing Guides](#).